Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 85, Issue 5, Pages 548-552Publisher
WILEY
DOI: 10.1038/clpt.2008.295
Keywords
-
Categories
Funding
- Meijer Lavino Foundation for Cardiac Research, Aalst, Belgium
Ask authors/readers for more resources
Stem cell-based cardiovascular regenerative medicine offers the next frontier of therapy through delivery of progenitor cells to achieve structural and functional repair of the myocardium. Initial clinical experience indicates that such therapy is feasible and safe, yet structural and functional benefits remain rather modest. A common pitfall in all studies is the very low rate of cell retention by the recipient myocardial tissue. This limitation warrants lead optimization so as to improve the outcome of stem cell delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available